Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus WEGOVY.
MOUNJARO (AUTOINJECTOR) vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Subcutaneously once weekly; initial dose 2.5 mg for 4 weeks, then increase to 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated; maximum 15 mg weekly.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
Terminal elimination half-life ~5 days (117 hours), supporting once-weekly dosing.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Renal: negligible; Fecal: primarily via biliary elimination as intact peptide; total clearance ~0.056 L/h.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist